Brief: Viatris Launches Inpefa, Expanding Its Heart Failure Portfolio And Broadening Presence In Cardiovascular Diseases
20/01/2026 12:10
Jan 20 (Reuters) - Viatris Inc VTRS.O: VIATRIS EXPANDS INNOVATIVE PORTFOLIO IN CARDIOVASCULAR DISEASES WITH THE COMPANY'S FIRST LAUNCH OF INPEFA® (SOTAGLIFLOZIN) FOR THE TREATMENT OF HEART FAILURE Source text: [ID:] Further company coverage: VTRS.O (Reporting by Kunal Das) ((Kunal.Das2@thomsonreuters.com;))
Recent news on Viatris
See all newsBrief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal